A major milestone in diabetes management in India, Cipla Limited is given the go-ahead from the Central Drugs Standard Control Organisation (CDSCO) to distribute and market Afrezza, a product of inhaled insulin from MannKind Corporation of the USA. This will go a long way in revolutionising diabetes care throughout India.

What is Afrezza?
Afrezza (insulin human) Inhalation Powder is a rapid-acting insulin for delivery via an inhaler, which offers a needle-free alternative in managing diabetes.

Key features of Afrezza include:

• Onset: Works within 12 minutes, mimicking the body's natural response of insulin.

• Short action: Lasting for 2-3 hours with an ideal usage for post-meal sugary spikes.

• Convenience: Delivered by oral inhalation, eliminating the need for multiple daily injections of insulin.

• Target population: Suitable for adult patients with both Type 1 and Type 2 diabetes mellitus.

Cipla's Aim:
The Managing Director and Global CEO of Cipla, Umang Vohra-Owing to our continuing technological innovation:
"Afrezza provides an option for the patient-centered management of diabetes, offering an alternative that lessens their requirement for multiple daily insulin injections. This provides a lot of assistance to someone who is particularly averse to needles, enabling appropriate management of their condition."

Clinical and Global History:
Efficacy of Afrezza has been proven in over 70 clinical studies taken by more than 3,000 patients. Approved about a decade ago in the US, the drug has been in prescribed usage for tens of thousands of patients. MannKind Corporation will supply the product to Cipla, which will handle distribution, sales, and marketing across India.

Why India Should Care:
India being a global hotspot for diabetes, the development of this drug could transform the lives of millions of patients. This is the first and only non-injectable insulin currently available for diabetes management, thus allowing for much greater convenience and adherence on the part of patients.
As Cipla continues its pioneering efforts in inhalation therapy, its collaboration with MannKind will allow for increased access to the new solution, thus ensuring better glycemic control and improved quality of life for the Indian diabetic patient.